PIM447 dihydrochloride is a potent, orally bioavailable, and selective pan-PIM kinase inhibitor with dual anti-tumor and bone-protective effects; it inhibits multiple myeloma (MM) cell proliferation, induces apoptosis in sensitive MM cell lines (e.g., MM1S, NCI-H929, RPMI-8226), promotes caspase and PARP cleavage, causes G0/G1 cell cycle arrest, and demonstrates in vivo efficacy in controlling tumor progression and reducing serum hIgλ levels in a mouse model of bone marrow-disseminated human multiple myeloma; additionally, it increases bone volume density and trabecular number while reducing trabecular separation.